XML 15 R39.htm IDEA: XBRL DOCUMENT v2.4.0.6
Actavis Transactions (Details) (USD $)
1 Months Ended 12 Months Ended 0 Months Ended 12 Months Ended 36 Months Ended 12 Months Ended 0 Months Ended
Apr. 20, 2011
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Jul. 02, 2010
Collaborative arrangement [Member]
Mar. 03, 2010
Collaborative arrangement [Member]
Dec. 31, 2012
Collaborative arrangement [Member]
Dec. 31, 2010
Collaborative arrangement [Member]
Dec. 31, 2012
Collaborative arrangement [Member]
Dec. 31, 2012
Beneficial owner [Member]
Dec. 31, 2011
Beneficial owner [Member]
Dec. 31, 2010
Beneficial owner [Member]
Jul. 02, 2010
Minimum [Member]
Collaborative arrangement [Member]
Jul. 02, 2010
Maximum [Member]
Collaborative arrangement [Member]
Jun. 01, 2010
Term loan promissory note [Member]
Jul. 02, 2010
Actavis [Member]
Collaborative arrangement [Member]
Related Party Transaction [Line Items]                                
Stock issued during period, shares, issued for noncash consideration           11,200,000                    
Face amount of debt                             $ 15,000,000  
Notes payable interest accrual rate                             4.00%  
Prepayment fee                             2,000,000  
Proceeds from sale of assets 3,100,000 0 0 15,000,000 47,000,000                      
Potential cash payment amount         45,500,000                      
Amount of milestone payment         5,000,000                     5,000,000
Nonpayable Milestone Payment, Amount                         6,000,000 8,000,000    
General and administrative   8,570,094 8,108,194 14,716,339       4,200,000                
Royalty revenue percentage                         0.10 0.20    
Conditional Royalty Reduction Percentage         50.00%   1.00%                  
Gross Profit Entitlement In Lieu of Third Party Commercialization         20.00%                      
Research and Development Arrangement Contract to Perform for Others, Amount                           7,000,000    
Research and Development Expense   770,642 2,779,058 8,581,874         10,600,000              
Reimbursement Revenue                   435,199 3,196,601 0        
Amount Of Cap Exceeded On Agreed Research And Developent Costs                 3,600,000              
Product Sales Price Based On Cost of Good Sold         110.00%                      
Shares issued in connection with the elimination of intangible assets         11,800,000                      
Assets of Disposal group, including discontinued operation         16,200,000                      
Extinguishment of debt, amount         15,000,000                      
Deferred revenue, revenue recognized   0 0 265,168                        
Royalties             10,000,000                  
Reimbursement Payment, Acquisiiton Operating Expenses               $ 1,100,000